We aimed to review the development of the chemoradiotherapy options used in the treatment of locally advanced, unresectable or medically inoperable Stage III non-small-cell lung cancer (NSCLC) patients with this review. There are many differences about extent and localization of disease for locally advanced stage NSCLC. The optimal management depends upon multiple factors, including the specific combination of tumor (T) and node (N) staging parameters, the potential to achieve a complete surgical resection of all disease if indicated, and the patient's overall condition and preferences. Chemoradiotherapy has always been the cornerstone of treatment of locally advanced NSCLC and techniques have significantly advanced over this time. Radiatio...
Survival of all non-small cell lung cancer (NSCLC) patients is disappointing, with a 5-year survival...
Technical advances in stereotactic radiotherapy have resulted in marked improvements in local contro...
Locally advanced, stage IIIA-N2 Non-small cell lung cancer (NSCLC) represents a heterogeneous patien...
AbstractLocally advanced non-small cell lung cancer (NSCLC) is a multifaceted disease that is challe...
Surgery alone is currently still accepted as the principal therapy for cure for patients with locali...
BACKGROUND: In patients with non-small cell lung cancer (NSCLC), approximately 25% have locally adva...
AbstractApproximately a third of patients with newly diagnosed non-small cell lung cancer (NSCLC) ha...
Definitive radiochemotherapy is the standard treatment for many patients with locally advanced nonsm...
Definitive radiochemotherapy is the standard treatment for many patients with locally advanced nonsm...
Locally advanced non-small cell lung cancer is a heterogeneous disease with typically poor outcomes....
Chemoradiotherapy, the standard of care for locally advanced non–small-cell lung cancer (NSCLC), oft...
Abstract Lung cancer is the second most common and the deadliest type of cancer worldwide. Clinicall...
Surgical treatment of stage IIIA non-small cell lung cancer (NSCLC) remains a controversial area in ...
Locally advanced Non-small cell lung cancer (NSCLC) is a commonly encountered diagnosis. Historicall...
Locally advanced non-small cell lung cancer (NSCLC) has historically been defined as Stage III by th...
Survival of all non-small cell lung cancer (NSCLC) patients is disappointing, with a 5-year survival...
Technical advances in stereotactic radiotherapy have resulted in marked improvements in local contro...
Locally advanced, stage IIIA-N2 Non-small cell lung cancer (NSCLC) represents a heterogeneous patien...
AbstractLocally advanced non-small cell lung cancer (NSCLC) is a multifaceted disease that is challe...
Surgery alone is currently still accepted as the principal therapy for cure for patients with locali...
BACKGROUND: In patients with non-small cell lung cancer (NSCLC), approximately 25% have locally adva...
AbstractApproximately a third of patients with newly diagnosed non-small cell lung cancer (NSCLC) ha...
Definitive radiochemotherapy is the standard treatment for many patients with locally advanced nonsm...
Definitive radiochemotherapy is the standard treatment for many patients with locally advanced nonsm...
Locally advanced non-small cell lung cancer is a heterogeneous disease with typically poor outcomes....
Chemoradiotherapy, the standard of care for locally advanced non–small-cell lung cancer (NSCLC), oft...
Abstract Lung cancer is the second most common and the deadliest type of cancer worldwide. Clinicall...
Surgical treatment of stage IIIA non-small cell lung cancer (NSCLC) remains a controversial area in ...
Locally advanced Non-small cell lung cancer (NSCLC) is a commonly encountered diagnosis. Historicall...
Locally advanced non-small cell lung cancer (NSCLC) has historically been defined as Stage III by th...
Survival of all non-small cell lung cancer (NSCLC) patients is disappointing, with a 5-year survival...
Technical advances in stereotactic radiotherapy have resulted in marked improvements in local contro...
Locally advanced, stage IIIA-N2 Non-small cell lung cancer (NSCLC) represents a heterogeneous patien...